retatrutide type 2 diabetes phase 2 trial hba1c ADA 2026: Revolution Phase 2 Trial of Retatrutide

Clinical Studies Overview Of Clinical Studies The safety and effectiveness of insulin glargine given once-daily at bedtime was compared to that of once-daily and twice-daily NPH insulin in open-label, randomized, active-controlled, parallel studies of 2,327 adult patients and 349 pediatric patients with type 1 diabetes mellitus and 1,563 adult patients with type 2 diabetes mellitus (see Tables 9-11)

Contact your pharmacist or medication manufacturers medical information line with specific details for guidance

Same panel composition as urine in most commercial offerings

For someone with severe obesity facing immediate health consequences, this additional efficacy could prove decisive